Age‐related changes in fluid biomarkers and cognitive abilities in a non‐human primate model of AD pathology

Abstract

Background: Current immunotherapeutic approaches for Alzheimer's disease (AD) are limited in their effectiveness and face complications associated with cerebral amyloid angiopathy (CAA), such as amyloid‐related imaging abnormalities (ARIA).